Salovum® to lower tumor pressure, inflammation, and oxygen deficits in glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial implants probes during a standard diagnostic brain biopsy to measure intratumoral pressure, microdialysis for cytokines, and partial oxygen pressure. Participants ingest Salovum® starting 24–72 hours after the biopsy, and researchers compare measurements taken before and during Salovum® intake. The product is an egg yolk–derived preparation rich in antisecretory factor, previously shown to lower intracranial pressure in preclinical and some clinical head-injury contexts. The study focuses on short-term physiological effects on pressure, inflammation, oxygenation, and tumor volume rather than long-term clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Suspected glioblastoma
2. Age 18-75 years
3. Planned diagnostic biopsy
4. Informed consent of subject

Exclusion Criteria:

1\. Known egg yolk allergy

Where it's running

• Department of Neurosurgery, Skane University Hospital
  Lund, Sweden Recruiting

Study contacts

• Principal investigator: Peter Siesjö, MD, PhD — Skane University Hospital
• Study coordinator: Peter Siesjö, MD, PhD.
• Email: peter.siesjo@skane.se
• Phone: +46705655778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Lixumistat window of opportunity in newly diagnosed glioblastoma

  This study tests whether Lixumistat can benefit adults with newly diagnosed glioblastoma who are planned for surgical tumor removal.

  Recruiting Early Phase 1 University of Miami · Miami, Florida · NCT07884344

• Glioblastoma in Réunion: an epidemiological and socio-anthropological look at patients and care

  A large group of adults with diffuse gliomas in Réunion is being studied to understand how biology, culture, and health care pathways affect diagnosis and treatment.

  Recruiting Centre Hospitalier Universitaire de la Réunion · Saint-Pierre · NCT07865195

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• Maintenance radiotherapy after standard glioblastoma treatment

  This study tests whether a single 2 Gy maintenance radiotherapy dose after standard treatment is safe and feasible for adults with newly diagnosed glioblastoma.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07831772

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.